These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

94 related items for PubMed ID: 2797345

  • 21. Treatment of IgA nephropathy: corticosteroids, tonsillectomy, and mycophenolate mofetil.
    Kawamura T.
    Contrib Nephrol; 2007; 157():37-43. PubMed ID: 17495435
    [Abstract] [Full Text] [Related]

  • 22. IgA nephropathy: prognostic significance of proteinuria and histological alterations.
    Kobayashi Y, Tateno S, Hiki Y, Shigematsu H.
    Nephron; 1983; 34(3):146-53. PubMed ID: 6348567
    [Abstract] [Full Text] [Related]

  • 23. Combination therapy of prednisone and ACE inhibitor versus ACE-inhibitor therapy alone in patients with IgA nephropathy: a randomized controlled trial.
    Lv J, Zhang H, Chen Y, Li G, Jiang L, Singh AK, Wang H.
    Am J Kidney Dis; 2009 Jan; 53(1):26-32. PubMed ID: 18930568
    [Abstract] [Full Text] [Related]

  • 24. Controlled, prospective trial of steroid treatment in IgA nephropathy: a limitation of low-dose prednisolone therapy.
    Katafuchi R, Ikeda K, Mizumasa T, Tanaka H, Ando T, Yanase T, Masutani K, Kubo M, Fujimi S.
    Am J Kidney Dis; 2003 May; 41(5):972-83. PubMed ID: 12722031
    [Abstract] [Full Text] [Related]

  • 25. Steroid and cyclophosphamide therapy for IgA nephropathy associated with crescenteric change: an effective treatment.
    McIntyre CW, Fluck RJ, Lambie SH.
    Clin Nephrol; 2001 Sep; 56(3):193-8. PubMed ID: 11597033
    [Abstract] [Full Text] [Related]

  • 26. Comparison of immunosuppressive therapies for IgA nephropathy after tonsillectomy: three-course versus one-course steroid pulse combined with mizoribine.
    Kaneko T, Arai M, Ikeda M, Morita M, Watanabe Y, Hirama A, Shimizu A, Tsuruoka S.
    Int Urol Nephrol; 2015 Nov; 47(11):1823-30. PubMed ID: 26433884
    [Abstract] [Full Text] [Related]

  • 27. Clinicopathologic findings relevant to disappearance or relapse of proteinuria following corticosteroid treatment in IgA nephropathy patients with proteinuria of 0.5 to 2.0 g/day.
    Suzuki T, Yamamoto T, Ohura M, Fujigaki Y, Yonemura K, Kimura M, Hishida A.
    Clin Exp Nephrol; 2004 Sep; 8(3):243-9. PubMed ID: 15480902
    [Abstract] [Full Text] [Related]

  • 28. Can immunosuppressive drugs slow the progression of IgA nephropathy?
    Goumenos D, Ahuja M, Shortland JR, Brown CB.
    Nephrol Dial Transplant; 1995 Sep; 10(7):1173-81. PubMed ID: 7478120
    [Abstract] [Full Text] [Related]

  • 29. ANCA-associated crescentic glomerulonephritis with mesangial IgA deposits.
    Haas M, Jafri J, Bartosh SM, Karp SL, Adler SG, Meehan SM.
    Am J Kidney Dis; 2000 Oct; 36(4):709-18. PubMed ID: 11007672
    [Abstract] [Full Text] [Related]

  • 30. Advanced IgA nephropathy: to treat or not to treat?
    Locatelli F, Pozzi M, Del Vecchio L, Pozzi C.
    Nephron Clin Pract; 2003 Oct; 93(4):c119-21. PubMed ID: 12759578
    [No Abstract] [Full Text] [Related]

  • 31. Factors predicting progression of IgA nephropathies.
    Coppo R, D'Amico G.
    J Nephrol; 2005 Oct; 18(5):503-12. PubMed ID: 16299675
    [Abstract] [Full Text] [Related]

  • 32. Steroids in the treatment of IgA nephropathy to the improvement of renal survival: a systematic review and meta-analysis.
    Zhou YH, Tang LG, Guo SL, Jin ZC, Wu MJ, Zang JJ, Xu JF, Wu CF, Qin YY, Cai Q, Gao QB, Zhang SS, Yu DH, He J.
    PLoS One; 2011 Apr 12; 6(4):e18788. PubMed ID: 21533280
    [Abstract] [Full Text] [Related]

  • 33. "Point of no return (PNR)" in progressive IgA nephropathy: significance of blood pressure and proteinuria management up to PNR.
    Komatsu H, Fujimoto S, Sato Y, Hara S, Yamada K, Morita S, Eto T.
    J Nephrol; 2005 Apr 12; 18(6):690-5. PubMed ID: 16358226
    [Abstract] [Full Text] [Related]

  • 34. Recurrence of IgA nephropathy with nephrotic syndrome in renal allograft.
    Pettersson E, Honkanen E, Törnroth T.
    Nephron; 1985 Apr 12; 41(1):114-7. PubMed ID: 3897883
    [Abstract] [Full Text] [Related]

  • 35. Review of cases of IgA nephropathy.
    World MJ.
    J R Army Med Corps; 2013 Jun 12; 159(2):90-3. PubMed ID: 23720589
    [Abstract] [Full Text] [Related]

  • 36. Mycophenolic acid therapy after cyclophosphamide pulses in progressive IgA nephropathy.
    Rasche FM, Keller F, von Müller L, Sailer LK, Karges W, Czock D.
    J Nephrol; 2006 Jun 12; 19(4):465-72. PubMed ID: 17048204
    [Abstract] [Full Text] [Related]

  • 37. Natural history of immunoglobulin A nephropathy and predictive factors of prognosis: a long-term follow up of 204 cases in China.
    Lv J, Zhang H, Zhou Y, Li G, Zou W, Wang H.
    Nephrology (Carlton); 2008 Jun 12; 13(3):242-6. PubMed ID: 18221258
    [Abstract] [Full Text] [Related]

  • 38. [Long-term administration of cyclosporine A in patients with IgA nephropathy].
    Chábová V, Tesar V, Zabka J, Rychlík I, Merta M, Jirsa M, Stejskalová A, Stejskal J.
    Cas Lek Cesk; 1996 Dec 18; 135(24):803-6. PubMed ID: 9072300
    [Abstract] [Full Text] [Related]

  • 39. IgA nephropathy: a long-term progressive study.
    Orłowski T, Górski A, Rancewicz Z, Morzycka-Michalik M, Smogorzewski M, Małdyk M, Lao M, Szczesny-Nowicka B.
    Miner Electrolyte Metab; 1990 Dec 18; 16(1):54-6. PubMed ID: 2325593
    [Abstract] [Full Text] [Related]

  • 40. [Clinicopathological study on IgA nephritis].
    Akimoto M.
    Nihon Jinzo Gakkai Shi; 1989 Jan 18; 31(1):77-90. PubMed ID: 2747002
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 5.